Stock Scorecard



Stock Summary for Pieris Pharmaceuticals Inc (PIRS) - $16.01 as of 11/20/2024 8:35:13 PM EST

Total Score

12 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PIRS

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PIRS

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PIRS

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PIRS

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PIRS (32 out of 90)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 0
Price to Earnings (Max of 10) 0

Latest News for for PIRS

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Lifecore Biomedical ( NASDAQ:LFCR ) 10/17/2024 11:30:00 AM
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS 8/13/2024 5:53:00 PM
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings - Anitra ( AMEX:AZTR ) , Lamb Weston Hldgs ( NYSE:LW ) 7/24/2024 6:37:00 PM
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results - Tesla ( NASDAQ:TSLA ) 7/24/2024 4:30:00 PM
StockNews.com Initiates Coverage on Pieris Pharmaceuticals ( NASDAQ:PIRS ) 7/12/2024 5:19:00 AM
StockNews.com Initiates Coverage on Pieris Pharmaceuticals ( NASDAQ:PIRS ) 7/12/2024 5:16:00 AM
Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors 7/8/2024 12:15:00 PM
Pieris Pharmaceuticals ( NASDAQ:PIRS ) Earns Hold Rating from Analysts at StockNews.com 7/4/2024 8:17:00 AM
StockNews.com Begins Coverage on Pieris Pharmaceuticals ( NASDAQ:PIRS ) 6/26/2024 5:26:00 AM
Pieris Pharmaceuticals ( NASDAQ:PIRS ) Earns Hold Rating from Analysts at StockNews.com 6/18/2024 5:18:00 AM

Financial Details for PIRS

Company Overview

Ticker PIRS
Company Name Pieris Pharmaceuticals Inc
Country USA
Description Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anti-calcium protein-based drugs in the United States. The company is headquartered in Boston, Massachusetts.
Sector Name TRADE & SERVICES
Industry Name SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 16.01
Price 4 Years Ago 200.00
Last Day Price Updated 11/20/2024 8:35:13 PM EST
Last Day Volume 8,045
Average Daily Volume 25,651
52-Week High 22.32
52-Week Low 6.20
Last Price to 52 Week Low 158.23%

Valuation Measures

Trailing PE N/A
Industry PE 122.49
Sector PE 41.04
5-Year Average PE -184.72
Free Cash Flow Ratio 1.09
Industry Free Cash Flow Ratio 30.25
Sector Free Cash Flow Ratio 94.88
Current Ratio Most Recent Quarter 4.77
Total Cash Per Share 14.69
Book Value Per Share Most Recent Quarter 21.64
Price to Book Ratio 1.12
Industry Price to Book Ratio 5.37
Sector Price to Book Ratio 9.15
Price to Sales Ratio Twelve Trailing Months 1.01
Industry Price to Sales Ratio Twelve Trailing Months 10.17
Sector Price to Sales Ratio Twelve Trailing Months 2.18
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 1,320,200
Market Capitalization 21,136,402
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 26.43%
Reported EPS 12 Trailing Months -18.69
Reported EPS Past Year -6.72
Reported EPS Prior Year -3.79
Net Income Twelve Trailing Months -15,928,000
Net Income Past Year -24,500,000
Net Income Prior Year -33,300,000
Quarterly Revenue Growth YOY -97.30%
5-Year Revenue Growth 8.03%
Operating Margin Twelve Trailing Months -0.57

Balance Sheet

Total Cash Most Recent Quarter 19,400,000
Total Cash Past Year 19,700,000
Total Cash Prior Year 26,400,000
Net Cash Position Most Recent Quarter 19,400,000
Net Cash Position Past Year 19,700,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 18,705,000
Total Stockholder Equity Prior Year 26,758,000
Total Stockholder Equity Most Recent Quarter 16,268,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -27,986,000
Free Cash Flow Per Share Twelve Trailing Months -21.20
Free Cash Flow Past Year -53,990,000
Free Cash Flow Prior Year -60,973,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.06
MACD Signal 0.02
20-Day Bollinger Lower Band 8.61
20-Day Bollinger Middle Band 15.45
20-Day Bollinger Upper Band 22.29
Beta 0.66
RSI 45.15
50-Day SMA 13.80
150-Day SMA 80.45
200-Day SMA 129.89

System

Modified 11/19/2024 10:12:16 AM EST